Drugmakers’ Secret Royalty Payments to Fauci’s NIAID Exploded After Pandemic: Report

Secret royalty payments from drug companies to scientists, researchers, executives, and other employees of the National Institutes for Health (NIH) exploded following the Coronavirus Pandemic in 2021, according to a new report from a non-profit government watchdog.

“In 2022 and 2023, pharmaceutical and healthcare companies paid the [NIH] a sum of $710,381,160 in third-party royalties. These were payments healthcare companies made to NIH, its leadership and scientists to license medical inventions created in federal, taxpayer-funded labs,” OpenTheBooks.com reports in an analysis being made public Monday as former NIAID Director Anthony Fauci testifies before the House Select Subcommittee on the Coronavirus Pandemic. The Epoch Times obtained a copy of the full report.

“The National Institute of Allergies and Infectious Diseases (NIAID), led until recently by Dr. Anthony Fauci, collected nearly all of it: $690,218,610 of the $710 million,” the report said.

Read Full Article Here
Fauci by shealah_craighead is licensed under flickr https://creativecommons.org/publicdomain/mark/1.0/

Follow us

Read our latest news on any of these social networks!

Get latest news delivered daily!

We will send you breaking news right to your inbox

Have a tip? Let us know!

Recent Articles

Pentagon Funds Lab-Grown Meat Initiative

One contract will fund research for novel cell culture methods and military rations.

RFK Jr. Campaign Fundraising Slumps in May: Filings

The Kennedy campaign’s overall income dropped by nearly $14 million between April and May, according to federal disclosures.

567,000 Portable Chargers Sold at Costco Recalled After Reports of Fires

The recall followed two reports of residential fires involving the portable chargers.

Washington Gov. Jay Inslee stockpiles abortion pills in ‘resistance’ to potential second Trump presidency

This is despite Trump previously stating that he would leave the issue of abortion to the states.